Silverman L R, Deligdisch L, Mandeli J, Greenspan E M
Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York.
Cancer Invest. 1994;12(2):145-55. doi: 10.3109/07357909409024870.
Angiosarcoma of the breast is a rare and highly malignant neoplasm with few long-term survivors. Little is known about the effects of chemotherapy for patients with disseminated disease or its role in the adjuvant setting. We report the case of a patient with metastatic angiosarcoma of the breast who achieved a long-term clinical and pathological remission after treatment with methotrexate. The 30-year course of her disease is the longest reported survival with documented metastatic angiosarcoma of the breast. Analysis of the role of chemotherapy in the adjuvant setting and its effects in relation to histological subtype is undertaken. Adjuvant chemotherapy for patients with poorly differentiated angiosarcoma of the breast results in a higher proportion of patients relapse-free (29.2%) compared to patients not receiving adjuvant chemotherapy (4.4%) (p < 0.05). Patients with well-differentiated tumors do not appear to derive benefit from adjuvant chemotherapy. The effects for patients with disseminated disease are reported.
乳腺血管肉瘤是一种罕见且高度恶性的肿瘤，长期存活者很少。对于播散性疾病患者化疗的效果或其在辅助治疗中的作用知之甚少。我们报告了一例乳腺转移性血管肉瘤患者，该患者在接受甲氨蝶呤治疗后实现了长期的临床和病理缓解。她30年的病程是有记录的乳腺转移性血管肉瘤患者中报道的最长生存期。本文对化疗在辅助治疗中的作用及其与组织学亚型的关系进行了分析。与未接受辅助化疗的患者（4.4%）相比，乳腺低分化血管肉瘤患者接受辅助化疗后无复发生存的比例更高（29.2%）（p<0.05）。高分化肿瘤患者似乎未从辅助化疗中获益。本文还报告了播散性疾病患者的化疗效果。
